AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

PHASE2CompletedINTERVENTIONAL
Enrollment

725

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Anxiety Disorders
Interventions
DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

Placebo

2 tablets taken twice a day for 28 days

Trial Locations (52)

Unknown

Research Site, Birmingham

Research Site, Tucson

Research Site, Arcadia

Research Site, Beverly Hills

Research Site, Cerritos

Research Site, Chino

Research Site, Encino

Research Site, Los Alamitos

Research Site, Novato

Research Site, Oceanside

Research Site, San Diego

Research Site, Norwich

Research Site, Fort Myers

Research Site, Miami

Research Site, Pembroke Pines

Research Site, Saint Petersberg

Research Site, Tampa

Research Site, Winter Park

Research Site, Atlanta

Research Site, Marietta

Research Site, Smyrna

Research Site, Libertyville

Research Site, Park Ridge

Research Site, Indianapolis

Research Site, Overland Park

Research Site, Baltimore

Research Site, Boston

Research Site, Cambridge

Research Site, St Louis

Research Site, Clementon

Research Site, Fresh Meadows

Research Site, Mount Kisco

Research Site, New York

Research Site, Rochester

Research Site, Raleigh

Research Site, Winston-Salem

Research Site, Bismarck

Research Site, Beechwood

Research Site, Cincinnati

Research Site, Middleburg Heights

Research Site, Oklahoma City

Research Site, Portland

Research Site, Jenkintown

Research Site, Norristown

Research Site, Memphis

Research Site, Friendswood

Research Site, San Antonio

Research Site, Salt Lake City

Research Site, Woodstock

Research Site, Herndon

Research Site, Spokane

Research Site, Middleton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY